Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open Gastro

Supplementary Table 2

	Patients with Abnormal ALT (>1x ULN) (n=152)	Patients with all normal Liver enzymes (n=788)	P-value
Age	56.7 ± 11.9	59.4 ± 13.6	0.02
Sex			<0.01
M	101 (66.5%)	329 (41.8%)	
F	51 (33.6%)	459 (58.3%)	
BMI	30.7 ± 6.2	28.1 ± 5.6	<0.01
Obesity (BMI≥30)	73 (48.3%)	235 (29.9%)	<0.01
Alcohol intake (Within limits: ≤21 units M, ≤14 units F)			<0.01
Non-drinker	23 (15.3%)	164 (21.4%)	
Within limits	98 (65.3%)	528 (68.8%)	
Above limits	29 (19.3%)	75 (9.8%)	
AUDIT – C			
Low risk	61 (40.4%)	480 (61.3%)	<0.01
High risk	90 (59.6%)	302 (38.6%)	
Hypertension	58 (38.2%)	254 (32.3%)	0.16
Type II Diabetes	24 (15.8%)	93 (11.8%)	0.17
Metabolic syndrome (Harmonised criteria)	81 (55.5%)	312 (40.3%)	<0.01
Triglyceride	1.8 ± 1.3	1.2 ± 0.7	<0.01
HDL-cholesterol	1.3 ± 0.4	1.5 ± 0.5	<0.01
FLI	74.4 ± 27.5	47.3 ± 30.2	<0.01
FLI group			<0.01
Low	18 (12.7%)	283 (36.6%)	
Intermediate	16 (11.3%)	208 (26.9%)	

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open Gastro

High	108 (76.1%)	283 (36.6%)	
FIB-4 score	1.54 ± 1.04	1.27 ± 0.64	<0.01
Age-adjusted FIB-4 score			<0.01
Low	74 (52.5%)	618 (79.1%)	
Intermediate	57 (40.4%)	139 (17.8%)	
High	10 (7.1%)	24 (3.1%)	
QRisk2	15.8 ± 14.0	15.70 ± 12.8	0.95

Supplementary Table 1: Comparison of patient demographics between patients with abnormal ALT and patients with all normal liver enzymes